Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
P/E ratio for Co-Diagnostics, Inc. (CODX)
P/E ratio as of 2023: -1.10
According to Co-Diagnostics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.10. At the end of 2022 the company had a P/E ratio of -5.57.
P/E ratio history for Co-Diagnostics, Inc. from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.10 |
| 2022 | -5.57 |
| 2021 | 7.03 |
| 2020 | 5.85 |
| 2019 | -2.47 |
| 2018 | -2.97 |
| 2017 | -4.16 |
| 2016 | -33.32 |
| 2015 | -31.45 |
| 2014 | -43.54 |